Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

The trial enrolled patients aged 12 years and older whose specific skin sites were affected by plaque psoriasis of at least moderate severity. The data were part of a presentation at the ongoing ...

I broke out in guttate, inverse, and plaque psoriasis from head to toe. It lasted for seven months. For those seven months, I didn’t feel like myself. The pain was constant. I couldn’t be ...

The ICONIC-TOTAL study, conducted by Protagonist's collaboration partner, Johnson & Johnson, evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least ...

Plaque psoriasis, a chronic inflammatory skin condition, affects up to half of psoriasis patients on the scalp, where the presence of hair can complicate topical treatment application. Scalp ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp ... and was published online on May 7 in JAMA Dermatology. The short duration ...

“They leave it out of the discussion,” he says. “For patients who have the most common type of psoriasis, plaque psoriasis, there is not a clear, established relationship with thyroid ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...